JDJaime G. Deville

Jaime G. Deville

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jaime G. Deville has a total of 126 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of Three Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV/ΔNS2/Δ1313/I1314L, RSV/6120/ΔNS2/1030s, and RSV/276 in RSV Seronegative Children

    by Coleen K Cunningham, Ruth A Karron, Elizabeth J McFarland, Mark J Giganti, Rachel Ketchum, Charlotte Perlowski, Jennifer Libous, Haley Brozik, Jennifer Oliva, Dwight E Yin, et al.

    Background: A respiratory syncytial virus (RSV) vaccine, eliciting active immunity could significantly impact child health. This study evaluated 3 intranasal live-attenuated candidate RSV vaccines, RSV/ΔNS2/Δ1313/I1314L, RSV/6120/ΔNS2/1030s, and RSV/276 to placebo. Methods: Healthy, RSV-seronegative children aged 6–24 monthswere randomized to receive 1 of 3 candidate vaccines or placebo. Participants were monitored for vaccine reactogenicity and RSV serum antibodies. Results: Between years 2019 and 2023, 67 participants were randomized, 20 each to RSV/ΔNS2/Δ1313/I1314L, RSV/6120/ΔNS2/1030s, and placebo and 7 to RSV/276. The RSV/276 arm closed early due to an excess of mild cough in another study. The proportion (95% CI) of children experiencing at least 1 solicited adverse event during the 28 days after inoculation was 55% (32%, 77%) in RSV/ΔNS2/Δ1313/I1314L, 40% (19%, 64%) in RSV/6120/ΔNS2/1030s, 71% (29%, 96%) in RSV/276, and 55% (32%, 77%) in placebo. Events were mostly Grade 1 and often associated with other viruses. The proportion of children with ≥4-fold increase in serum RSV-neutralizing antibody titer in each vaccine arm (>70%) was significantly greater than the placebo arm (15%). Conclusions: RSV/ΔNS2/Δ1313/I1314L and RSV/6120/ΔNS2/1030s had excellent safety and immunogenicity;assessment of RSV/276 was limited by the small sample size. RSV/ΔNS2/Δ1313/I1314L and RSV/6120/ΔNS2/1030s were deemed suitable for further evaluation. Clinical Trials Registration: NCT03916185.

  • Top Cited Papers
    Open Access

    Real-world clinical impact of plasma cell-free DNA metagenomic next-generation sequencing assay

    by Ishminder Kaur, Bennett Shaw, Ashrit Multani, Christine Pham, Sanchi Malhotra, Ethan Smith, Kristina Adachi, Paul Allyn, Zackary Bango, Omer Eugene Beaird, et al.

    Objective: To describe the real-world clinical impact of a commercially available plasma cell-free DNA metagenomic next-generation sequencing assay, the Karius test (KT). Methods: We retrospectively evaluated the clinical impact of KT by clinical panel adjudication. Descriptive statistics were used to study associations of diagnostic indications, host characteristics, and KT-generated microbiologic patterns with the clinical impact of KT. Multivariable logistic regression modeling was used to further characterize predictors of higher positive clinical impact. Results: We evaluated 1000 unique clinical cases of KT from 941 patients between January 1, 2017–August 31, 2023. The cohort included adult (70%) and pediatric (30%) patients. The overall clinical impact of KT was positive in 16%, negative in 2%, and no clinical impact in 82% of the cases. Among adult patients, multivariable logistic regression modeling showed that culture-negative endocarditis (OR 2.3; 95% CI, 1.11–4.53; P .022) and concern for fastidious/zoonotic/vector-borne pathogens (OR 2.1; 95% CI, 1.11–3.76; P .019) were associated with positive clinical impact of KT. Host immunocompromised status was not reliably associated with a positive clinical impact of KT (OR 1.03; 95% CI, 0.83–1.29; P .7806). No significant predictors of KT clinical impact were found in pediatric patients. Microbiologic result pattern was also a significant predictor of impact. Conclusions: Our study highlights that despite the positive clinical impact of KT in select situations, most testing results had no clinical impact. We also confirm diagnostic indications where KT may have the highest yield, thereby generating tools for diagnostic stewardship.


  • Open Access

    Academic Health Centers and Humanitarian Crises: One Health System’s Response to Unaccompanied Children at the Border

    by Sherin U. Devaskar, Coleen K. Cunningham, Robin H. Steinhorn, Cynthia Haq, Johnese Rn Spisso, William Dunne, Juan Raul Gutierrez, Coleen Md Kivlahan, Michelle Bholat, Suzanne Barakat, et al.

    University of California Health (UCH) provided a system-wide, rapid response to the humanitarian crisis of unaccompanied children crossing the southern U.S. border in the midst of the COVID-19 pandemic in 2021. In collaboration with multiple federal, state, and local agencies, UCH mobilized a multidisciplinary team to deliver acute general and specialty pediatric care to unaccompanied children at 2 Californian emergency intake sites (EISs). The response, which did not disrupt normal UCH operations, mobilized the capacities of the system and resulted in a safe and developmentally appropriate environment that supported the physical and mental health of migrant children during this traumatic period. The capacities of UCH’s 6 academic health centers ensured access to trauma-informed medical care and culturally sensitive psychological and social support. Child life professionals provided access to exercise, play, and entertainment. Overall, 260 physicians, 42 residents and fellows, 4 nurse practitioners participated as treating clinicians and were supported by hundreds of staff across the 2 EISs. Over 5 months and across both EISs, a total of 4,911 children aged 3 to 17 years were cared for. A total of 782 children had COVID-19, most infected before arrival. Most children (3,931) were reunified with family or sponsors. Continuity of care after reunification or placement in a long-term shelter was enhanced by use of an electronic health record. The effort provided an educational experience for residents and fellows with instruction in immigrant health and trauma-informed care. The effort benefitted from UCH’s recent experience of providing a system-wide response to the COVID-19 pandemic. Lessons learned are reported to encourage the alignment and integration of academic health centers’ capacities with federal, state, and local plans to better prepare for and respond to the accelerating need to care for those in the wake of disasters and humanitarian crises.


  • Aureobasidium pullulansvar.melanigenumfungemia in a pediatric patient

    by Kileen L. Mershon-Shier, Jaime G. Deville, Shirley Delair, Annette W. Fothergill, Brian Wickes, G. Sybren de Hoog, Deanna A. Sutton, Michael A. Lewinski

    This report describes a chronically ill child who presented with high fever and was diagnosed with catheter-related sepsis. Aureobasidium pullulans variety melanigenum, a dematiaceous fungus that rarely causes opportunistic infections, was recovered from multiple blood cultures. Antifungal susceptibilities were performed and the minimum inhibitory concentration (MIC) for fluconazole was 64 mg/l, suggestive of fluconazole resistance. The patient made a full recovery after removal of the catheter line and treatment with liposomal amphotericin B. This is the first case report of an elevated in vitro fluconazole MIC of an A. pullulans isolate and only the third case of successful treatment of A. pullulans fungemia.


  • Open Access

    Outcomes of Neonatal Candidiasis: The Impact of Delayed Initiation of Antifungal Therapy

    by Heather Cahan, Jaime G. Deville

    Objective/Methods. To determine the outcomes of invasive neonatal candidiasis before institution of routine antifungal prophylaxis, we conducted a retrospective review of cases of invasive candidiasis in newborns in a referral-based neonatal intensive care unit located in a single tertiary academic center between January 1998 and December 2002.Results. Sixty-three newborns with invasive neonatal candidiasis were identified. Overall mortality rate was 35%. Virtually every infant had a central venous catheter (CVC), required mechanical ventilation and previous administration of antibacterial agents. Delayed institution of antifungal therapy was associated with increased mortality. In addition, length of hospitalization, duration of prior antibacterial therapy, mechanical ventilation, and CVC use, as well as evidence of end-organ disease, were associated with an adverse outcome.Conclusions. Reliance on available laboratory tools in cases of invasive neonatal candidiasis can result in delayed diagnosis and increased mortality. A risk-factor-based approach to empirical treatment could be justified in this setting.


  • Open Access

    Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1–infected children

    by Courtney V. Fletcher, Jaime G. DeVille, Pearl M. Samson, John H. Moye, Joseph A. Church, Hans M.L. Spiegel, Paul Palumbo, Terence Fenton, M. Elizabeth Smith, Bobbie Graham, et al.


  • Cellular and humoral immune responses to a tetanus toxoid booster in perinatally HIV-1-infected children and adolescents receiving highly active antiretroviral therapy (HAART)

    by Natascha Ching, Jaime G. Deville, Karin A. Nielsen, Bonnie Ank, Lian S. Wei, Myung Shin Sim, Steven M. Wolinsky, Yvonne J. Bryson

    Human immunodeficiency virus type 1 (HIV-1) infected children treated with highly active antiretroviral therapy (HAART) may develop a significant reduction of plasma viremia associated with an increase in CD4+ T-cell counts. Functional capacity of this reconstituted immune system in response to recall antigens is important to maintain protective immunity to vaccine-preventable diseases. We therefore determined cellular and humoral immune responses to tetanus toxoid (TT) booster in perinatally HIV-1-infected children and adolescents receiving HAART. Immune responses were prospectively evaluated pre- and post-tetanus booster using lymphocyte proliferation assay (LPA) stimulation index (SI≥3.0) and tetanus antibody (TAb≥0.15) in 15 patients. The median interval from primary tetanus immunization series was 6 years (range 2–12 years). We compared patients by their virological response to HAART (complete responders, CR, n=7; incomplete responders, ICR, n=8). There were no significant differences in median age 12.6 years (CR: 12.9; ICR: 10.6) or median CD4 T-cell pre-booster (CR: 35%/819; ICR: 26%/429) between groups. Tetanus LPA responses were observed in one patient prior to booster and in seven patients post-booster. In contrast, 38% of patients had protective TAb pre-booster, but 92% developed protective TAb post-booster. All of the CR and 5/6 ICR patients developed protective TAb. HIV-1-infected children and adolescents had modest LPA responses to tetanus following booster, similar to HIV-1-infected adults. However, the majority of patients developed protective TAb levels after booster and maintained the response. Shorter intervals may need to be considered for TT immunization boosters in HIV-1-infected pediatric patients, as only 38% had protective TAb at baseline.


  • Nocardia asteroides brain abscesses and meningitis in an immunocompromized 10-year-old child

    by Emilie Chow, Theodore Moore, Jaime Deville, Karin Nielsen

    Nocardiosis is an uncommon pediatric infection. We describe the successful treatment of Nocardia brain abscesses and meningitis in an immunocompromized boy with a history of both liver and bone marrow transplants.